Treatment of erythromelalgia with active wine-cooler and amitriptyline-ketamine-gel: A case report and literature review;Behandlung der erythromelalgie mit aktivem weinkühler und amitriptylin-ketamin-gel - Fallbericht mit aktueller literaturübersicht

Phlebologie

Volumn 36, Issue 3, 2007, Pages 151-155

  Klein Weigel, Peter ^a   Olges, K ^a   Wolbergs, S ^a   Koning Ch ^a   Brackertz, R ^a   Flessenkaemper, I ^a  

^a German Red Cross Hospital   (Germany)

Author keywords

Amitriptyline; Channelopathy; Erythromelalgia; Erythrothermalgia; Ketamine; Microcirculation; Neuropathy

Indexed keywords

AMITRIPTYLINE; KETAMINE; VOLTAGE GATED SODIUM CHANNEL;

ACTION POTENTIAL; ADULT; ARTICLE; CASE REPORT; CHANNELOPATHY; COMPREHENSION; DISEASE CLASSIFICATION; DRUG EFFECT; ERYTHROMELALGIA; FEMALE; FOOT; GEL; HUMAN; HUMAN CELL; LITERATURE; MICROANGIOPATHY; MUTATION; NOCICEPTION; NOCICEPTIVE RECEPTOR; PAIN; SELF CARE; SENSORY NERVE CELL; SYMPATHETIC NERVE CELL; TOE; WINE;

EID: 34547119272     PISSN: 0939978X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1622179     Document Type: Article

References (42)

1. Burns TM, Te Morsche RH, Jansen JB et al. Genetic heterogeneity and exclusion of a modifying locus at 2q in a family with autosomal dominant primary erythermalgia. Br J Dermatol 2005; 153: 174-177.
2. Cannon SC. An expanding view for the molecular basis of familial periodic paralysis. Neuromuscul Disord 2002; 12: 533-543.
3. Cummins TR, Dib-Hajj SD, Waxman SG. Electrophysiological properties of mutant Nav 1.7 sodium channels in a painful inherited neuropathy. J Neurosci 2004; 24: 8232-8236.
4. Davis MD, Weenig RH, Genebriera J et al. Histopathologic findings in primary erythromelalgia are nonspecific: special studies show a decrease in small nerve fiber density. J Am Acad Dermatol 2006; 55: 519-522.
5. Davis MD, Wilkins F, Rooke TW. Between episodes of erythromelalgia: a spectrum of colors. Arch Dermatol 2006; 142: 1085-1086.
6. Davis MD, Rooke T. Erythromelalgia. Curr Treat Options Cardiovasc Med 2006; 8: 153-165.
7. Davis MD, Sandroni P, Rooke TW et al. Erythromelalgia: vasculopathy, neuropathy, or both? A prospective study of vascular and neurophysiologic studies in erythromelalgia. Arch Dermatol 2003; 139: 1337-1343.
8. rd et al. Natural history of erythromelalgia: presentation and outcome in 168 patients. Arch Dermatol 2000; 136: 330-336.
9. Dib-Hajj SD, Rush AM, Cummins TR. Gain-of-function mutation in Nav 1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain 2005; 128: 1847-1854.
10. Djouhri L, Newton R, Levinson SR et al. Sensory and electrophysiological properties of guinea-pig sensory neurones expressing Nav 1.7 (PN1) Na+ channel alpha subunit protein. J Physiol 2003; 546: 565-576.
11. Drenth JP, te Morsche RH, Guillet G et al. SCN9A mutations define primary erythermalgia as a neuropathic disorder of voltage gated sodium channels. J Invest Dermatol 2005; 124: 1333-1338.
12. Drenth JP, Finley WH, Breedveld GJ et al. The primary erythermalgia-susceptibility gene is located on chromosome 2q31-32. Am J Hum Genet 2001; 68: 1277-1282.
13. Drenth JP, Vuzevski V, van Joost T et al. Cutaneous pathology in primary erythermalgia. Am J Dermatopathol 1996; 18: 30-34.
14. Drenth JP, Michiels JJ. Erythromelalgia and erythermalgia: diagnostic differentiation. Int J Dermatol 1994; 33: 393-397.
15. Felix R. Channelopathies: Ion channel defects linked to heritable clinical disorders. J Med Genet 2000; 37: 729-740.
16. Han C, Rush AM, Dib-Hajj SD et al. Sporadic on-set of erythermalgia: a gain-of-function mutation in Nav1.7. Ann Neurol 2006; 59: 553-558.
17. Jørgensen HP, Sondergaard J. Pathogenesis of erythromelalgia. Arch Dermatol 1978; 114: 112-114.
18. Kalgaard OM, Mork C, Kvernebo K. Prostacyclin reduces symptoms and sympathetic dysfunction in erythromelalgia in a double-blind randomized pilot study. Acta Derm Venereol 2003; 83: 442-444.
19. Klugbauer N, Lacinova L, Flockerzi V et al. Structure and functional expression of a new member of the tetrodotoxin-sensitive voltage-activated sodium channel family from human neuroendocrine cells. EMBO J 1995; 14: 1084-1090.
20. Kullmann DM, Hanna MG. Neurological disorders caused by inherited ion-channel mutations. Lancet Neurol 2002; 1: 157-166.
21. Kvernebo K, Seem E. Erythromelalgia - pathophysiological and therapeutic aspects. A preliminary report. J Oslo City Hosp 1987; 37: 9-12.
22. Lehmann-Horn F, Jurkat-Rott K. Voltage-gated ion channels and hereditary disease. Physiol Rev 1999; 79: 1317-1372.
23. Lerche H, Weber YG, Jurkat-Rott K et al. Ion channel defects in idiopathic epilepsies. Curr Pharm Des 2005; 11: 2737-2752.
24. Littleford RC, Khan F, Belch JJ. Impaired skin vasomotor reflexes in patients with erythromelalgia. Clin Sci (Lond) 1999; 96: 507-512.
25. Littleford RC, Khan F, Belch JJ. Skin perfusion in patients with erythromelalgia. Eur J Clin Invest 1999; 29: 588-593.
26. Michiels JJ, te Morsche RH, Jansen JB et al. Autosomal dominant erythermalgia associated with a novel mutation in the voltage-gated sodium channel alpha subunit Nav1.7. Arch Neurol 2005; 62: 1587-1590.
27. Michiels JJ, Drenth JP. Erythromelalgia and erythermalgia: lumpers and splitters. Int J Dermatol 1994; 33: 412-413.
28. Mitchell SW. On a rare vaso-motor neurosis of the extremities, and on the maladies with which it may be confounded. Am J Med Sci 1878; 76.
29. Mork C, Asker CL, Salerud EG et al. Microvascular arteriovenous shunting is a probable pathogenetic mechanism in erythromelalgia. J Invest Dermatol 2000; 114: 643-646.
30. Mork C, Salerud EG, Asker CL et al. The prostaglandin E1 analog misoprostol reduces symptoms and microvascular arteriovenous shunting in erythromelalgia-a double-blind, crossover, placebo-compared study. J Invest Dermatol 2004; 122: 587-593.
31. Mørk C, Kvernebo K, Asker CL, Salerud EG. Reduced skin capillary density during attacks of erythromelalgia implies arteriovenous shunting as pathogenetic mechanism. J Invest Dermatol 2002; 119: 949-953.
32. Nassar MA, Stirling LC, Forlani G et al. Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain. Proc Natl Acad Sci USA 2004; 101: 12706-12711.
33. Sandroni P, Davis MD. Combination gel of 1% amitriptyline and 0.5% ketamine to treat refractory erythromelalgia pain: a new treatment option? Arch Dermatol 2006; 142: 283-286.
34. Sangameswaran L, Fish LM, Koch BD et al. A novel tetrodotoxin-sensitive, voltage-gated sodium channel expressed in rat and human dorsal root ganglia. J Biol Chem 1997; 272: 14805-14809.
35. Smith LA, Allen EV. Erythermalgia (erythromelalgia) of the extremities: a syndrome characterized by redness, heat, and pain. Am Heart J 1938; 16: 175-188.
36. Staub DB, Munger BL, Uno H et al. Erythromelalgia as a form of neuropathy Arch Dermatol 1992; 128: 1654-1655.
37. Sugiyama Y, Hakusui S, Takahashi A et al. Primary erythromelalgia: the role of skin sympathetic nerve activity. Jpn J Med 1991; 30: 564-567.
38. Toledo-Aral JJ, Moss BL, He ZJ et al. Identification of PN1, a predominant voltage-dependent sodium channel expressed principally in peripheral neurons. Proc Natl Acad Sci USA 1997; 94: 1527-1532.
39. Uno H, Parker F. Autonomic innervation of the skin in primary erythermalgia. Arch Dermatol 1983; 119: 65-71.
40. Van Genderen PJ, Lucas IS, van Strik R et al. Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation. Thromb Haemost 1996; 76: 333-338.
41. Waxman SG, Dib-Hajj SD. Erythromelalgia: a hereditary pain syndrome enters the molecular era. Ann Neurol 2005; 57: 785-788.
42. Yang Y, Wang Y, Li S et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet 2004; 41: 171-174.